BlackRock Now Holds 7.8% Of Editas Medicine, A Stake Of 11.9 Million Shares
The asset manager's passive filing lists 11,937,882 Editas shares and says none were bought to influence control of the gene-editing company.
BlackRock beneficially owns 11,937,882 shares of Editas Medicine, or 7.8% of the common stock, according to a passive ownership filing (Schedule 13G) made Tuesday. Editas, which develops CRISPR-based gene editing medicines, had a market value of $369 million as of Tuesday.
Sole voting power over most of the shares
BlackRock reported sole voting power over 11,732,765 of the shares and shared voting power over none. The filing lists September 30, 2026 as the event date.
The filing is the kind required of holders at or above 5% of a company's stock, and BlackRock's position clears that line. The stake is spread across several BlackRock units, including BlackRock Fund Advisors and BlackRock Institutional Trust Company.
An ordinary-course holder, BlackRock certifies
BlackRock certified that the shares were acquired and are held in the ordinary course of business, and not to change or influence control of Editas. The filing adds that various persons have the right to receive dividends or sale proceeds from the stock, and that no one person's interest exceeds 5% of the outstanding shares.
A CRISPR company built on licensing
Editas develops gene editing medicines that use CRISPR technology, focused on treatments delivered inside the patient's body. Its lead program, EDIT-401, is an experimental one-time therapy meant to lower LDL cholesterol, and it remains in preclinical work.
The company earns money by licensing its CRISPR patents and collaborating with other drug developers, according to its annual report. Vertex holds a non-exclusive license for its Cas9 technology, and Bristol Myers Squibb, through its Juno Therapeutics subsidiary, collaborates with it on engineered T cell therapies.
The 7.8% is measured on the filing's cover-page basis, which counts warrants, options or convertibles exercisable within 60 days in both the holding and the share base.
Sources
- SCHEDULE 13G — BlackRock, Inc. re: Editas Medicine, Inc. (EDIT) — SEC EDGAR
- SCHEDULE 13G Exhibit 99 — EXHIBIT 99: ITEM 7 — SEC EDGAR